Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.
The Covid pandemic didn’t just kill people directly. It appears to have accelerated a long-brewing reversal in US heart failure deaths, with mortality climbing faster since 2020 after years of decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results